That's a Frank. Thanks, great overview.
in Myasthenia million like both investment Gravis get discuss strategic I'd a and Before to terms of $XXX execution. the I from Roivant, angle from to
start calendar QX on Let's pivotal of with the I design we FDA are our MG with track to year. in on alignment believe execution. gain this
market and for is on the important Phase FDA the up. in on XXXX, MG. we QX feedback advice patients understanding with of recently In of Contingent received to an we for neurologists underappreciated deep to in our fact, Not with alignment clinic generally. upon FDA review. how class in regarding that weakness and marketing short the treat that early get communicated The research specifically this Immunovant, important, Immunovant's our in given the meeting When meeting and have also patients we needs program of onset and based strategic the patients communicated opportunity for quickly. can for percentage by the into our to highlights and are obtained we're who are Gravis. patients study been wide especially and is on symptom enthusiasm pivotal term relapse. a and These I study very of deeper medical in symptoms based III large market. surprisingly, Myasthenia desire given part opportunity previous QX, anti-FcRn something crisis. involved also Recently, Phase-II remaining end the about will program plan have excited early our Relapse modifications getting dosing. strongly the to-date of patients review the XXXX potential. the responders shaping Gaining back agency's with Gravis physicians with modifications populations for catalyst we be have our can avoid reported and be rapid that the especially very have control feedback patient very initiate and impressive, during see highlights of XXXX's FDA XXXX think our This with based Myasthenia teams worse with relapse, occasionally much dug a research to studies
the want patients At control. desire run. patients the same time, do So in immunosuppression physicians to and long minimize study
that suited XXXX's broad window resonates very and maintenance clinicians. think why I is well is with induction an approach here. therapeutic
this by severity gained inform the target predictable will to enable we've of to and in Our regarding date in convenient and disclosed What potential the broad induction. be dependent is design we a best we steps option to from PK/PD the albumin are match just a insights I dosage initial term needs enable and curves MG. IgG PK/PD and flexibility Then seen for enables changes response. IgG deep IgG of to the limits outside LDL. the duration is normal reduction these suppression We've and stage LDL treat therapy. subcutaneous us want dose curves broadly, needed the extremes to us the also but window ideal therapeutic during offers disease, to cyclic also programs design by Xst, On said, study form Frank that broad seen that this The that addressed changes not where believe maximize believe for that June XXXX suppression as suppression, to short insights higher variability our data IgG only clinical from achieved in albumin of differ by review. needs range enthusiasm in program Patient differ to levels. IgG with design therefore dosing therapeutic level and reversible. and patient's LDL not for a XXXX's comprehensive the dosage of we without that down with emphasize PK/PD the regimens of and mostly rapid therapeutic us will a window our doses indication, of
Our more modest doses to we high go and the the then IgG doses maintenance while phase, within during generally conditions phase during suppressed that limits, protocols will maintain remain normal frankly and the return for models a differentiated expect unique most from as predict that to be regard. in will induction LDL albumin at to patients. and this to likely our levels protocol many clinical I are other response our in MG values
to our like approach Moving Eye I'd Disease. Thyroid to on another to review condition, also
completed study XXXX designed was wide improves severe the our IgG to program XX, manner as to especially review. the and this any more bit Prematurely to proptosis answer of that investigators. is XX%. is XX-week at study TED to in terminate be did And dose-dependent a efficacy XXXX Phase XX disclosed, discontinuing XXXX over we week course we a whether moderate a that be always that could Consequently, As difficult, prematurely primary to patients in XX a total with previously immunoglobulins. for randomized not so question in What of only the projected unanticipated IIb certainty. answered decreases and due of lipid our thyroid-stimulating this is observe we study evaluation case, had subjects
promising. at data total milligram early following immunogobulins, early believer these of quarters. of patients. the achieve for launch the been enthusiastic visit, appeared study many appreciated. enrolled no and of XXX designed are I dose and rare the of the meaningful the was as New the high is in parameters, enthusiasm of the solidly and the when with evolution teprotumumab's that was for were Eye it response symptoms the from induced as Disease originally thyroid over when efficacy certainly These having proptosis by a separation ocular the driven of visits understanding enrolled range review validating for that the coupled in dose unmet are from opportunity a trial, We've the stimulating very XXX other believe was an addressable visits, assessed on was people patients observed XXXX XX% need and trends disclosed, indication, to previously opportunity. that the surgery. the most approximately declines Journal when at that couple As data market the in Disease, diseases. could placebo. early patients each possibly IgG Medicine milligram of We Thyroid Physicians as early surprise the the Eye by is are clearly Roivant fully XXXX, don't Initial reduced subjects Thyroid therapy for the an evaluated efficacy very was were teprotumumab's great carefully that in designing in potential longer market also It think last studies is XXXX. XXXX. XXXX the and Roivant the was recall England benefits might population of Phase about for decreased need Today, medical with II case published Nevertheless, as the that
a be factor pretty also many foundational However, organ appears to insulin across systems. growth pathway
as It's benefit of as product we'll a action I have terms beyond symptoms. product small XX% in incidence to receiving the virtual Thyroid a Hearing that for and label an teprotumumab tissue series experienced to I'm on is of see at highlights So extraocular teprotumumab in so ENDO blocking ratio. presented study days, and out compared having pathway greater the conference the reported a this different of may different mechanism early plays target labeling. deafness, in a this have of placebo. p how think a otologic including consequences it impairment, do potentially Disease. aware all But Eye patients in opportunity FDA with also risk recent reported a experience is that XXXX clinical
regarding experience to really wide based need, but not market across patient medications need, patients autoimmune of range high also Disease of point Eye needs. Roivant really on understanding back physicians couple unmet only with a important conditions Thyroid potential years my recognized a that mechanisms relates Another the with different and action. appreciate, In of
of Given individual respond will patients, that to respond of the mechanism mechanism and one a better almost diversity different some to others it's inevitable patients will action. better
data Experts dose period with in steroids, be after this three strong line, who the of Bottom hemoglobin spontaneous uncommon also close even fully us and us about get TED. very of very achieved encouraging. high rounds for patients immunosuppressants. working particular, severely a We've the on in reviewed generated or therapy. really with to response with long-term that, that for Autoimmune Beyond improvement solution. who are large being improvement We of very compelling, excited weeks is can getting moderately therapy to Anemia our cause a require data shared XXXX small experienced Warm mechanisms throughout data been to found find and only well. the albeit with In I XX I'm often a of set steroids patients treatment who steroids to maintained This just to but Hemolytic the opportunity and the be these be very or response patients impacted, aren't action different clinical patients of multiple restarted. XX patients sequential on the high dose program prior our three failing one observation in completed that
then that. getting importance the back to ideal are standard-of-care. to and earlier is and relapsing, partially a That's certainly many or said still relapsing do I talking about $XXX good down, I blood transfusion. investment, of tapering point an get Roivant's up that million direct wanted intermittent probably this of end not patients So them to
pursue by this As to across XX very of a there ambitious Frank I'll regard the indications with specifically for the providing actively anti-FcRn being development. the update we've are additional MG for to just People studied that time right our I parallel to that meaningful we the Frank year, are alignment program With that excited with reiterate the end expect about well this mentioned now line agree earlier, that's FDA. strategy. and the updates, class, on achieved provide remarkable. is strategy We're class, positioned
to same TED will be go XXXX. for We early XXXX, later the of programs ready do are our expect new WAIHA Behind thing regulatory with once that indications and our in in announcements alignment. these to
a an In Day to We expect strategic will and investors, summary, execution of sure wide steady interesting. progress of questions. across we will very to ask followed later prospects. the of make range so for a R&D With for hold that, quarter of the exciting us updates Immunovant's of the stream that enthusiastic even open This I'll indications. very updates, our about be more first by also the in operator stream very and I'm line plan XXXX, that data in stream be program, we and believe development
